* 僅供識別 — 1 — 1. 審議並批准繼續實施回購本公司部分A股股份方案。 2. 審議並批准授予董事會以下回購本公司H股（「H股」）的一般授權： (a) 在下文(b)、(c)及(d)段之規限下，董事會可於相關期間（定義見下文(e)段）內按照 中華人民共和國（「中國」）政府或證券監管機構、香港聯合交易所有限公司（「香 港聯交所」）或任何其他政府或監管機構之所有適用法律、法規及規例及╱或規定， 行使本公司全部權力在香港聯交所回購已發行H股； 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1513） 二零二五年第一次H股類別股東會通知 茲通知麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」）謹訂於二 零二五年五月二十九日（星期四）下午三時三十分（或緊隨本公司二零二五年第一次A股類 別股東會結束後或續會後）假座中國廣東省珠海市金灣區創業北路38號總部大樓六樓會議 室舉行二零二五年第一次H股類別股東 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通知的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通知全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1513） 召開二零二四年度股東大會的通知 茲通知麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」）謹訂於二 零二五年五月二十九日（星期四）下午二時正假座中國廣東省珠海市金灣區創業北路38號 總部大樓六樓會議室舉行二零二四年度股東大會（「年度股東大會」），議程如下： 一、會議基本情況 註1： 網絡投票系統由深圳證券交易所提供，僅適用於A股股東。 二、會議審議事項 6. 審議並批准向珠海市麗珠生物醫藥科技有限公司增資。 （二）特別決議案 7. 審議並批准本公司二零二四年度利潤分配預案（「二零二四年度利潤分配預案」）。 （一）普通決議案 — 1 ...

此乃要件 請即處理 閣下對本通函任何內容如有疑問，應諮詢 閣下的股票經紀或其他註冊證券交易商、銀行經理、律師、 專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有麗珠醫藥集團股份有限公司的股份，應立即將本通函交予買方或受讓人 或經手出售的銀行、股票經紀或其他代理商，以便轉交買方或受讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1513） (I)向麗珠生物增資 (II)二零二四年度利潤分配預案 董事會函件載於本通函第6至27頁。 本公司將於二零二五年五月二十九日（星期四）下午二時正，下午三時正（或緊隨年度股東大會結束或 續會之後）及下午三時三十分（或緊隨A股類別股東會結束或續會之後）在中國廣東省珠海市金灣區創業 北路38號總部大樓 ...

* For identication purpose only 僅供識別 Stock Code 股份代號 : 1513 (A joint stock company incorporated in the People's Republic of China with limited liability) （在中華人民共和國註冊成立的股份有限公司） www.livzon.com.cn 2024 Environmental, Social and Governance Report 環境、社會及管治報告 Evergreen Life, Bright Future & Wisdom 麗珠世界 生命常青 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. 環境、社會及管治報告 Environmental, Social and Governance Report 2024 | 1 關於本報告 | | 4 | | --- | --- | --- | | 2 董事長致辭 | | 8 | | 3 關於本公司 | | 12 | | 3.1 | 公司業務 | 13 | | 3.2 | ...

麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liability) （ 於 中 公 司 ） 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 Livzon Pharmaceutical Group Inc. (the "Company") Notification of publication of (1) Annual Report 2024; (2) Circular dated 24 April 2025; (3) Notice and Proxy Form of the Annual General Meeting for the Year 2024; and (4) Notice and Proxy Form of the 2025 First Class Meeting of H Shareholders (the "Current Corporate C ...

麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liability) （ 於 中 司 ） 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 (Stock code 股份代號: 1513) NOTIFICATION LETTER 通知信函 24 April 2025 Dear Non-Registered Holder(Note), Livzon Pharmaceutical Group Inc.(the "Company") Notification of publication of (1) Annual Report 2024; (2) Circular dated 24 April 2025; (3) Notice and Proxy Form of the Annual General Meeting for the Year 2024; and (4) N ...

Financial Performance - In 2024, Livzon Pharmaceutical Group achieved a revenue of RMB 11,812.34 million and a net profit attributable to shareholders of RMB 2,061.10 million[10]. - The company achieved a total revenue of RMB 12,430.04 million, with a year-on-year decrease of 4.97%[21]. - The net profit attributable to shareholders was RMB 1,953.65 million, reflecting a decline of 8.31% compared to the previous year[21]. - The company reported a net cash flow from operating activities of RMB 2,061.10 million, showing a significant increase of 51.80%[21]. - The company’s basic earnings per share for the year was RMB 2.10, with a diluted earnings per share of RMB 2.24[21]. - The company reported a total operating revenue for the year 2024 of RMB 11,812,338,854.68, representing a decrease of 4.97% compared to RMB 12,430,038,325.82 in 2023[106]. - The net profit attributable to shareholders increased by 5.50% to RMB 2,061,095.80 million in 2024[54]. - The company reported a gross margin of 45%, maintaining a stable margin compared to the previous year[37]. Research and Development - Research and development (R&D) investment accounted for 8.84% of total revenue, focusing on gastrointestinal, reproductive assistance, and mental health fields[14]. - The company has 45 products in the pipeline, including 23 innovative drugs and high-barrier complex formulations[14]. - Livzon has introduced six new projects through business development collaborations, enhancing its R&D pipeline[16]. - AI technology has been integrated into the entire R&D process, significantly improving efficiency[16]. - The company plans to increase investment in innovative drug research and development, focusing on core therapeutic areas such as digestive, mental health, and reproductive health[19]. - The company is focusing on self-research and business development (BD) to drive innovation, with a particular emphasis on gastrointestinal, reproductive, and neurological fields[73]. - The company has multiple products in various stages of clinical trials, including 3 in Phase III and 2 in Phase I[80]. - The company has established a modular and flat R&D management system to improve efficiency in project management and resource allocation[73]. Market Expansion - The company is expanding its market presence from emerging markets to Europe and the United States, optimizing its product offerings[17]. - Livzon is expanding its market presence in Southeast Asia, aiming to increase sales by 25% in that region[37]. - The company is actively pursuing international partnerships to introduce advanced technologies and expand its competitive products into global markets[93]. - The company has established branches in Malaysia and offices in Brazil, India, Spain, Vietnam, and Turkey to enhance its global commercialization strategy[101]. Product Development - Livzon plans to launch three new products in the next fiscal year, focusing on innovative drug development and biotechnology[37]. - The company has initiated Phase III clinical trials for a recombinant anti-IL-17A/F monoclonal antibody for psoriasis, aiming for market approval by 2025[76]. - The company has received approvals for three products during the reporting period, including potassium bismuth citrate granules and hydrochloride pramipexole tablets (8mg)[81]. - The company is focusing on high clinical value products, with a complete matrix of assisted reproductive products expected to enhance market presence[79]. - The company is advancing its research in traditional Chinese medicine, targeting mental health and chronic diseases, with two products expected to report this year[79]. Compliance and Sustainability - The company maintains a 100% compliance rate with GMP inspections for all production lines of listed products[18]. - The company has received MSCI ESG AAA rating for two consecutive years and was recognized as the "Best Progress Company" in the 2024 S&P Global Sustainability Yearbook[19]. - The company integrates sustainable development goals into management performance assessments, promoting green production and social responsibility[94]. - The company has established a standardized public welfare management system focusing on rural revitalization, education support, medical assistance, and disaster response, contributing to local farmers' income through the "Huangqi Industry Revitalization" project[95]. Financial Management - The company reported a total investment amount of RMB 1,711,305,473.04, representing a 134.54% increase compared to RMB 729,635,150.00 in the previous year[161]. - The company has established risk management measures for foreign exchange and commodity futures derivatives to mitigate market risks associated with currency and commodity price fluctuations[171]. - The company has not engaged in speculative derivative investments during the reporting period[172]. - The company has implemented strict internal controls to reduce operational risks related to derivative trading[171]. Customer and Supplier Relations - The average duration of the top five customers' relationship with the company is 16.60 years, indicating strong customer loyalty[114]. - The company’s total revenue from the top five customers was RMB 947,987,674.38, representing 8.10% of the total annual sales, slightly down from 8.19% in 2023[115]. - The total procurement amount from the top five suppliers was RMB 706,067,451.82, which accounted for 32.15% of the total procurement, an increase from 26.06% in 2023[119].

Revenue and Profit - The company's revenue for Q1 2025 was CNY 3,180,547,599.31, a decrease of 1.92% compared to CNY 3,242,814,513.73 in the same period last year[7] - Net profit attributable to shareholders increased by 4.75% to CNY 636,707,931.59 from CNY 607,823,809.46 year-on-year[7] - Basic and diluted earnings per share rose by 9.23% to CNY 0.71 from CNY 0.65 in the same period last year[7] - The company's operating revenue for the current period is RMB 3,180,547,599.31, a decrease of 1.92% from RMB 3,242,814,513.73 in the previous period[27] - The net profit attributable to shareholders of the parent company is RMB 636,707,931.59, up 4.76% from RMB 607,823,809.46 in the previous period[27] Cash Flow - The net cash flow from operating activities decreased by 21.59% to CNY 724,730,912.38 compared to CNY 924,248,920.31 in the previous year[7] - Total cash inflow from operating activities was RMB 3,427,996,327.57, down from RMB 3,508,763,815.99, reflecting a decline of 2.3%[29] - Cash outflow from operating activities increased to RMB 2,703,265,415.19, compared to RMB 2,584,514,895.68, marking an increase of 4.6%[29] - The net cash flow from investing activities was -RMB 221,749,900.37, an improvement from -RMB 457,336,601.18 in the previous period[29] - Cash inflow from investing activities totaled RMB 32,290,697.41, significantly higher than RMB 6,035,760.64 previously[29] - Cash outflow from investing activities decreased to RMB 254,040,597.78 from RMB 463,372,361.82, a reduction of 45.2%[29] - The net cash flow from financing activities was -RMB 487,915,315.07, an improvement from -RMB 654,613,688.15 in the previous period[29] - Total cash inflow from financing activities was RMB 630,140,000.00, down from RMB 721,939,862.90, a decrease of 12.7%[29] - The cash and cash equivalents at the end of the period amounted to RMB 10,821,444,006.06, slightly up from RMB 10,787,974,836.57[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 24,485,271,838.40, a slight increase of 0.12% from CNY 24,455,825,697.18 at the end of the previous year[8] - The company's equity attributable to shareholders increased by 2.19% to CNY 14,165,648,873.87 from CNY 13,862,334,189.33 at the end of the previous year[8] - The total liabilities decreased to RMB 9,109,970,328.17 from RMB 9,550,079,103.14, reflecting a reduction of approximately 4.62%[25] - Current assets totaled RMB 16,465,641,594.27, compared to RMB 16,419,980,644.30 at the beginning of the year[23] - Cash and cash equivalents stood at RMB 10,830,774,329.69, slightly up from RMB 10,827,146,984.92 at the start of the year[23] - The company's inventory decreased to RMB 1,900,256,033.70 from RMB 1,997,642,296.29 at the beginning of the year[23] - Long-term equity investments increased to RMB 1,061,082,396.62 from RMB 1,056,220,316.06[23] - The company has a total of 8,019,630,244.13 in non-current assets, slightly down from 8,035,845,052.88 at the beginning of the year[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,367, with 52,348 being A-share shareholders[16] - The company reported a total of 306,769,189 shares held by Hong Kong Central Clearing (Agent) Limited, representing 33.66% of the total shares[17] - Health元药业集团股份有限公司 holds 221,376,789 shares, accounting for 24.29% of the total shares[17] - The total number of shares repurchased by the company reached 9,425,955 A-shares, accounting for 1.03% of the total share capital, with a total expenditure of RMB 341,957,191.15[18] - The company also repurchased 7,245,300 H-shares, representing 0.80% of the total share capital, with a total expenditure of HKD 190,692,395.00[19] Expenses and Future Plans - Research and development expenses for the current period are RMB 216,076,782.61, down 9.25% from RMB 238,173,559.46 in the previous period[27] - The company reported a decrease in sales expenses to RMB 800,020,635.30 from RMB 876,113,247.33, a reduction of about 8.66%[27] - The company's financial expenses showed a slight improvement, with net financial income of RMB -56,040,353.34 compared to RMB -54,508,308.03 in the previous period[27] - The company plans to continue focusing on market expansion and new product development to drive future growth[27] Audit Information - The company did not undergo an audit for the first quarter report[30]

丽珠集团（000513）公告，2025年第一季度营业收入31.81亿元，同比下降1.92%；净利润6.37亿元，同 比增长4.75%。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年4月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...